$BTAI
BioXcel Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024007481 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $1.104M $582.0K
YoY Change 141.58% 182.52%
Cost Of Revenue $62.00K $80.00K
YoY Change 138.46% 788.89%
Gross Profit $1.042M $502.0K
YoY Change 141.76% 154.82%
Gross Profit Margin 94.38% 86.25%
Selling, General & Admin $9.450M $13.26M
YoY Change -63.47% -43.78%
% of Gross Profit 906.91% 2642.23%
Research & Development $8.032M $11.40M
YoY Change -70.22% -58.99%
% of Gross Profit 770.83% 2271.12%
Depreciation & Amortization $77.00K $78.00K
YoY Change -4.94% -2.5%
% of Gross Profit 7.39% 15.54%
Operating Expenses $17.48M $24.67M
YoY Change -66.92% -52.01%
Operating Profit -$17.30M -$24.16M
YoY Change -67.0% -52.8%
Interest Expense -$3.029M $3.607M
YoY Change -192.94% 7.13%
% of Operating Profit
Other Income/Expense, Net $12.03M $32.00K
YoY Change 2139.48% -113.01%
Pretax Income -$8.299M -$26.79M
YoY Change -84.49% -49.26%
Income Tax
% Of Pretax Income
Net Earnings -$8.299M -$26.79M
YoY Change -84.49% -49.26%
Net Earnings / Revenue -751.72% -4603.26%
Basic Earnings Per Share -$0.21 -$0.87
Diluted Earnings Per Share -$0.21 -$0.87
COMMON SHARES
Basic Shares Outstanding 37.53M 30.58M
Diluted Shares Outstanding 40.25M 30.87M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.27M $74.14M
YoY Change -55.88% -55.21%
Cash & Equivalents $56.27M $74.14M
Short-Term Investments
Other Short-Term Assets $1.643M $1.856M
YoY Change -64.56% -62.92%
Inventory $2.680M $2.439M
Prepaid Expenses
Receivables $812.0K $378.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $64.18M $80.92M
YoY Change -53.57% -54.35%
LONG-TERM ASSETS
Property, Plant & Equipment $629.0K $706.0K
YoY Change -33.16% -29.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $87.00K $87.00K
YoY Change 0.0% -90.59%
Total Long-Term Assets $1.254M $1.406M
YoY Change -32.65% -50.41%
TOTAL ASSETS
Total Short-Term Assets $64.18M $80.92M
Total Long-Term Assets $1.254M $1.406M
Total Assets $65.44M $82.32M
YoY Change -53.29% -54.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.26M $17.22M
YoY Change 18.33% 122.42%
Accrued Expenses $13.49M $13.68M
YoY Change -29.5% -19.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $27.29M $31.48M
YoY Change -21.46% 9.46%
LONG-TERM LIABILITIES
Long-Term Debt $103.0M $101.6M
YoY Change 6.36% 6.91%
Other Long-Term Liabilities $9.442M $21.57M
YoY Change 257.25% 558.29%
Total Long-Term Liabilities $103.0M $101.6M
YoY Change 6.36% 6.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.29M $31.48M
Total Long-Term Liabilities $103.0M $101.6M
Total Liabilities $139.7M $154.7M
YoY Change 4.1% 21.71%
SHAREHOLDERS EQUITY
Retained Earnings -$625.7M -$617.4M
YoY Change 20.82% 32.96%
Common Stock $40.00K $34.00K
YoY Change 37.93% 17.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$74.30M -$72.36M
YoY Change
Total Liabilities & Shareholders Equity $65.44M $82.32M
YoY Change -53.29% -54.29%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$8.299M -$26.79M
YoY Change -84.49% -49.26%
Depreciation, Depletion And Amortization $77.00K $78.00K
YoY Change -4.94% -2.5%
Cash From Operating Activities -$23.17M -$17.71M
YoY Change -39.34% -66.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.304M 26.63M
YoY Change 2021.6% 10.26%
NET CHANGE
Cash From Operating Activities -23.17M -17.71M
Cash From Investing Activities
Cash From Financing Activities 5.304M 26.63M
Net Change In Cash -17.87M 8.920M
YoY Change -52.94% -131.63%
FREE CASH FLOW
Cash From Operating Activities -$23.17M -$17.71M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001720893
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33632000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29930000
CY2024Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2024Q1 us-gaap Fair Value Recurring Basis Unobservable Input Reconciliation Liability Gain Loss Statement Of Income Extensible List
FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList
http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38410
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
BioXcel Therapeutics, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-1386754
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
555 Long Wharf Drive
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New Haven
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CT
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06511
CY2024Q1 dei City Area Code
CityAreaCode
475
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
238-6837
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2024Q1 dei Trading Symbol
TradingSymbol
BTAI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37530821
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74141000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65221000
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
378000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
71000
CY2024Q1 us-gaap Inventory Net
InventoryNet
2439000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1991000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2103000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2782000
CY2024Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1856000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2078000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
80917000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
72143000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
706000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
784000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
613000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
688000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
87000
CY2024Q1 us-gaap Assets
Assets
82323000
CY2023Q4 us-gaap Assets
Assets
73702000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
17220000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13654000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13675000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12424000
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
117000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
736000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31481000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27267000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
350000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
440000
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
21222000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1905000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101633000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
100598000
CY2024Q1 us-gaap Liabilities
Liabilities
154686000
CY2023Q4 us-gaap Liabilities
Liabilities
130210000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33632000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29930000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
34000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
544992000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
534060000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-617389000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-590598000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-72363000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-56508000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82323000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73702000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
582000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
206000
CY2024Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
80000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11401000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27800000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13264000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23595000
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
24745000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
51404000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24163000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-51198000
CY2024Q1 us-gaap Interest Expense
InterestExpense
3607000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3367000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
947000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2015000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-246000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.84
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30868000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28616000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
76775000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23918000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4877000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-27000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
53005000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-56508000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3709000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3433000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26791000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-72363000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-26791000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-52796000
CY2024Q1 us-gaap Depreciation
Depreciation
78000
CY2023Q1 us-gaap Depreciation
Depreciation
80000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
43000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
333000
CY2024Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
30000
CY2023Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-231000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3433000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4877000
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
1216000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
398000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
75000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
70000
CY2024Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
307000
CY2023Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
35000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
448000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-33000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-901000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2006000
CY2024Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
4826000
CY2023Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4654000
CY2024Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-619000
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1193000
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-83000
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-77000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17706000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52353000
CY2024Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
26743000
CY2023Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
24657000
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
117000
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
739000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
27000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
258000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26626000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
24149000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8920000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28204000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65221000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
193725000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74141000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165521000
CY2023Q1 btai Deferred Initial Public Offering Costs In Accrued Expense
DeferredInitialPublicOfferingCostsInAccruedExpense
596000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
224000
CY2024Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Note 1. Nature of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BioXcel Therapeutics, Inc. (“BTI” or the “Company”) is a biopharmaceutical company utilizing artificial intelligence (“AI”) approaches to develop transformative medicines in neuroscience and immuno-oncology. The Company is focused on utilizing cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BTI employs a unique AI platform to reduce therapeutic development costs and potentially accelerate timelines. The Company’s approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI management believes this differentiated approach has the potential to reduce the expense and time associated with drug development in diseases with substantial unmet medical needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As used in these condensed consolidated financial statements, unless otherwise specified or the context otherwise requires, the terms “BioXcel LLC” refers to the Company’s former parent and current significant stockholder, BioXcel LLC and, its predecessor, BioXcel Corporation. “OnkosXcel” refers to BTI’s wholly owned subsidiary for its advanced immuno-oncology assets, OnkosXcel Therapeutics, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On April 6, 2022, BTI announced that the United States (“U.S.”) Food and Drug Administration (“FDA”) approved IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> (dexmedetomidine or “Dex”) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is approved to be self-administrated by patients under the supervision of a health care provider. On July 6, 2022, BTI announced that IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, was commercially available in doses of 120 and 180 micrograms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s most advanced clinical development program is BXCL501. In indications other than those approved by the FDA as IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>, BXCL501 is an investigational proprietary, orally dissolving, film formulation of Dex for the treatment of agitation associated with psychiatric and neurological disorders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s advanced immuno-oncology asset, BXCL701, is an investigational, orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI was incorporated under the laws of the State of Delaware on March 29, 2017. The Company’s principal office is in New Haven, Connecticut. </p>
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74141000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-617389000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17706000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52353000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and notes thereto. Estimates are used in the following areas, among others: revenue recognition, derivative liabilities, stock-based compensation expense, accrued expenses and income taxes. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates.</span></p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The Company sells IGALMI</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">TM</sup><span style="font-weight:normal;"> through a drop-ship program under which orders from hospitals and similar health care institutions are processed through wholesalers, but shipments of the product are sent directly to the individual hospitals and similar health care institutions. BTI also contracts directly with certain hospitals, and intermediaries such as group purchasing organizations (“GPOs”). All trade accounts receivables are due from the distributor that fulfills orders on behalf of the Company.</span></p>
CY2024Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
2570000
CY2024Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8620000
CY2024Q1 us-gaap Revenue Recognition Accounting Policy Gross And Net Revenue Disclosure
RevenueRecognitionAccountingPolicyGrossAndNetRevenueDisclosure
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company’s revenues consist of product sales of IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">BTI recognizes revenue when its customers obtain control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition, BTI management performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The exercise of a material right may be accounted for as a contract modification or as a continuation of the contract for accounting purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company assesses whether the goods or services promised within each contract are distinct to identify those that are performance obligations. This assessment involves subjective determinations and requires management to make judgments about the individual promised goods or services and whether such goods and services are separable from the other aspects of the contractual relationship. Promised goods and services are considered distinct provided that: (i) the customer can benefit from the good or service either on its own or together with other resources that are readily available to the customer and (ii) the Company’s promise to transfer the good or service to the customer is separately identifiable from other promises in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company allocates the transaction price (the amount of consideration it expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company’s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI distributes IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> in the U.S. through arrangements with a distributor, wholesalers, and GPOs. The distributor and wholesalers help process and fulfill orders from hospitals on the Company’s behalf. The Company believes the hospitals are its customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company recognizes product revenues, net of consideration payable to customers, as well as variable consideration related to certain allowances and accruals that are determined using either the expected value or most likely amount method, depending on the type of the variable consideration, in its condensed consolidated financial statements at the point in time when control transfers to the customer, which is typically when the product has been delivered to the customer’s location. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. The Company’s only performance obligation identified for IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is to deliver the quantity of product ordered to the location specified by the customer’s order. The Company records shipping and handling costs associated with delivery of product to its customers within Selling, general and administrative expenses on its Condensed Consolidated Statements of Operations. Under the Company’s current product sales arrangements, BTI does not have contract assets (unbilled receivables), as it generally invoices its customer at the time of revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI sells IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> at wholesale acquisition cost less any agreed upon discounts, and calculates product revenue net of variable consideration and consideration payable to third parties associated with distribution of product. The Company records reserves, based on contractual terms, for the following components of consideration related to product sold during the reporting period. Calculating these amounts involves estimates and judgments, and the Company reviews these estimates quarterly and records any material adjustments in the period they are identified, which affects net product revenue and earnings in the period such variances occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Trade Discounts and Allowances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides the distributor and wholesalers with discounts for prompt payment and pays fees to the distributor, wholesalers and GPOs related to distribution of the product. BTI expects the relevant third parties to earn these discounts and fees, and therefore it deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Government Rebates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">IGALMI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup> is eligible for purchase by, or qualifies for reimbursement from, Medicaid and other U.S. government programs that are eligible for rebates on the price they pay for the product. To determine the appropriate amount to reserve for these rebates, BTI applies the applicable government discount to these sales, and estimates the portion of total rebates that it anticipates will be claimed. The Company deducts certain government rebates from gross product </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">revenue and accounts receivable at the time it recognizes the related revenue; other government rebates are recognized as an accrued liability at the time BTI recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Chargebacks</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI provides product discounts to hospitals associated with certain GPOs. The Company estimates the chargebacks that it expects to be obligated to provide based upon the terms of the applicable arrangements. BTI deducts such amounts from gross product revenue and accounts receivable at the time it recognizes the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 18pt;"><span style="font-style:italic;font-weight:bold;">Product Returns</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Company provides contractual return rights to its customers including the right to return product within six months of product expiration and up to 12 months after product expiration, as well as for incorrect shipments, and damaged or defective product, which the Company expects to be rare. Management expects product returns to be minimal, thus BTI recognizes a nominal allowance for product returns at the time of each sale. In the future, if any of these factors and/or the history of product returns changes, the Company will adjust the allowance for product returns.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">BTI classifies all fees paid to the distributor, other than those discussed above and those related to warehouse operations, as Selling, general and administrative expenses on its Condensed Consolidated Statements of Operations. Fees paid to the distributor for warehouse operations are classified as Cost of goods sold on BTI’s Condensed Consolidated Statements of Operations.</p>
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.60
CY2023 us-gaap Restructuring Charges
RestructuringCharges
4163000
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
935000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
935000
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
253000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
651000
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1251000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
405000
CY2024Q1 us-gaap Inventory Net
InventoryNet
2439000
CY2023Q4 us-gaap Inventory Net
InventoryNet
1991000
CY2024Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
45000
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1977000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1977000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1271000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1193000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
706000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
784000
CY2024Q1 us-gaap Depreciation
Depreciation
78000
CY2023Q1 us-gaap Depreciation
Depreciation
80000
CY2024Q1 btai Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
5156000
CY2023Q4 btai Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
6406000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1260000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
163000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6847000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5562000
CY2024Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
85000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
116000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
327000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
177000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13675000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12424000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
103896000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
102680000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2263000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2082000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
101633000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
100598000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
103896000
CY2024Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3564000
CY2023Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
3034000
CY2024Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
43000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
333000
CY2024Q1 us-gaap Interest Expense
InterestExpense
3607000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3367000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3433000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4877000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3433000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4877000
CY2024Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
287000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
391000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
65000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
743000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
40000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
703000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
353000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
350000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
353000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
99000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
99000
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1905000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2343000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-88000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
231000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1817000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2574000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-52796000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30868000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28616000
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.84
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14616000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5868000
CY2022Q2 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
10000000
CY2022Q2 us-gaap Longterm Purchase Commitment Period
LongtermPurchaseCommitmentPeriod
P3Y
CY2022Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
5000000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
btai-20240331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
0001558370-24-007481-index-headers.html Edgar Link pending
0001558370-24-007481-index.html Edgar Link pending
0001558370-24-007481.txt Edgar Link pending
0001558370-24-007481-xbrl.zip Edgar Link pending
btai-20240331.xsd Edgar Link pending
btai-20240331x10q.htm Edgar Link pending
btai-20240331x10q006.jpg Edgar Link pending
btai-20240331x10q007.jpg Edgar Link pending
btai-20240331xex31d1.htm Edgar Link pending
btai-20240331xex31d2.htm Edgar Link pending
btai-20240331xex32d1.htm Edgar Link pending
btai-20240331xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
btai-20240331_cal.xml Edgar Link unprocessable
btai-20240331_def.xml Edgar Link unprocessable
btai-20240331x10q_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
btai-20240331_pre.xml Edgar Link unprocessable